标准免疫抑制疗法联合异甘草酸镁治疗自身免疫性肝炎患者外周血B细胞和调节性B细胞变化*

doi:10.3969/j.issn.1672-5069.2023.06.017

摘要/Abstract

摘要： 目的观察应用标准免疫抑制疗法联合异甘草酸镁治疗自身免疫性肝炎(AIH)患者的疗效及其外周血调节性B细胞的变化。方法 2017年4月～2022年4月我院收治的108例AIH患者被分为对照组54例和观察组54例,分别接受标准的免疫抑制治疗方案或在此治疗的基础上加用异甘草酸镁口服治疗半年。采用免疫浊度试验法检测血清免疫球蛋白,使用流式细胞仪检测外周血B细胞和调节性B细胞百分比。结果在治疗半年末,观察组生化学应答率为85.2%,显著高于对照组的66.7%(P＜0.05);观察组血清ALT、AST和ALP水平分别为(51.2±7.6)U/L、(46.2±8.6)U/L和(67.4±2.4)U/L,均显著低于对照组【分别为(80.3±8.5)U/L、(75.7±6.4)U/L和(89.7±2.6)U/L,P<0.05】;两组血清IgG、IgM和血清GLO水平与对照组比无显著性统计学差异(P>0.05);观察组外周血CD19⁺B细胞、CD19⁺IL-10⁺B细胞、CD19⁺CD24^hiCD38^hi调节性B细胞和CD19⁺CD24^hiCD27⁺调节性B细胞百分比分别为(7.1±2.6)%、(0.6±0.2)%、(2.9±1.0)%和(5.7±1.3)%,均显著高于对照组【分别为(5.2±1.8)%、(0.4±0.1)%、(2.2±0.9)%和(4.3±1.2)%,P<0.05】,而CD19⁺CD27⁺CD38⁺⁺浆细胞和CD19⁺CD27^-CD38^-/+幼稚B细胞百分比分别为(4.2±1.2)%和(56.2±7.9)%,均显著低于对照组【分别为(6.5±1.7)%和(70.5±7.4)%,P<0.05】。结论应用标准的免疫抑制联合异甘草酸镁治疗AIH患者可提高生化学应答率,有助于改善肝功能,可能与对外周血调节性B细胞具有调节作用有关。

关键词: 自身免疫性肝炎, 标准的免疫抑制疗法, 异甘草酸镁, 调节性B细胞, 治疗

Abstract: Objective The aim of this study was to observe the efficacy and peripheral blood regulatory B cell subset changes in patients with autoimmune hepatitis (AIH) undergoing magnesium isoglycyrrhizinate and standard immunosuppressive therapy. Methods 108 patients with AIH were encountered in our hospital between April 2017 and April 2022, and were randomly divided into control (n=54) and observation (n=54) group, receiving standard immunosuppression treatment or oral magnesium isoglycyrrhizinate at base of it for six month. Serum immunoglobulin levels were detected by immunoturbidimetry, and peripheral blood B cell and regulatory B cell subsets were detected by FCM. Results At the end of six-month treatment, the biochemical response rate in the observation group was 85.2%, much higher than 66.7%(P＜0.05) in the control; serum ALT, AST and ALP level were (51.2±7.6)U/L, (46.2±8.6)U/L and (67.4±2.4)U/L, all significantly lower than[(80.3±8.5)U/L, (75.7±6.4)U/L and (89.7±2.6)U/L, respectively, P<0.05] in the control; there were no significant differences as respect to serum IgG, IgM and globulin levels between the two groups (P>0.05); the percentages of peripheral blood CD19⁺B cell, CD19⁺IL-10⁺B cell, CD19⁺CD24^hiCD38^hi regulatory B cell and CD19⁺CD24^hiCD27⁺ regulatory B cell were (7.1±2.6)%, (0.6±0.2)%, (2.9±1.0)% and (5.7±1.3)%, all significantly higher than [(5.2±1.8)%, (0.4±0.1)%, (2.2±0.9)% and (4.3±1.2)%, respectively, P<0.05], while the percentages of blood CD19⁺CD27⁺CD38⁺⁺ plasma cell and CD19⁺CD27^-CD38^-/+ naïve B cell were (4.2±1.2)% and (56.2±7.9)%, both much lower than [(6.5±1.7)% and (70.5±7.4)%, P<0.05] in the control. Conclusion The administration of standardized immunosuppressant and magnesium isoglycyrrhizinate combination therapy in the treatment of patients with AIH is efficacious, with a promising biochemical response, which might be related to the roles on modulation of peripheral blood regulatory B cells.

Key words: Autoimmune hepatitis, Standardized immunosuppression therapy, Magnesium isoglycyrrhizinate, Regulatory B cell, Therapy

陈雅君, 朱婧, 李璐, 何钦. 标准免疫抑制疗法联合异甘草酸镁治疗自身免疫性肝炎患者外周血B细胞和调节性B细胞变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 835-838.

Chen Yajun, Zhu Jing, Li Lu, et al. Peripheral blood regulatory B cell subset changes in patients with autoimmune hepatitis undergoing magnesium isoglycyrrhizinate and standard immunosuppressive therapy[J]. Journal of Practical Hepatology, 2023, 26(6): 835-838.

参考文献

[1] Arcos-Machancoses JV, Molera Busoms C, Julio Tatis E, et al.Accuracy of the simplified criteria for autoimmune hepatitis in children: systematic review and decision analysis. J Clin Exp Hepatol, 2019, 9(2): 147-155.
[2] Violatto MB, Casarin E, Talamini L, et al. Dexamethasone conjugation to biodegradable avidin-nucleic-acid-nano-assemblies promotes selective liver targeting and improves therapeutic efficacy in an autoimmune hepatitis murine model. ACS Nano, 2019, 13(4): 4410-4423.
[3] Dyson J K, Martin E D, Dalekos G N, et al. Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Aliment Pharmacol Ther, 2019, 49(5):528-536.
[4] PandyaW, Kumar V, Sachchidanand S, et al. Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-γ (RORγ or RORc) inhibitors: Hits and misses. J Med Chem, 2018, 61(24):10976-10995.
[5] 董亚云, 向阳. 护肝片联合恩替卡韦对老年慢性乙型肝炎患者疗效观察及对内皮功能和肝纤维化的影响. 中国老年学杂志, 2019, 39(20):4990-4992.
[6] 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗共识(2015年). 胃肠病学, 2016, 21(3): 165-178.
[7] Nielsen J, Nerup N, Møller S, et al. Minimally invasive assessment of hepatic function in children with indocyanine green elimination: a validation study. Scand J Gastroenterol, 2019, 54(4):485-491.
[8] Wang X, Zheng Z, Chen M, et al. Chylous ascites has a higher incidence after robotic surgery and is associated with poor recurrence-free survival after rectal cancer surgery. Chin Med J (Engl), 2021, 135(2):164-171.
[9] Zou X, Wang Y, Peng C. Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin induced model of liver injury. Int J Mol Med, 2018, 42(4):2020-2030.
[10] 王娟娟, 李春达. 护肝片联合替诺福韦酯治疗慢性乙型肝炎疗效观察及对患者细胞炎性因子和血管内皮功能的影响. 中国基层医药,2020,27(23):2841-2845.
[11] El-Khayat H, Yakoot M, El-Shabrawi M, et al. Treatment of chronic hepatitis C in adolescent patients with positive HBsAg or with occult hepatitis B: Is the risk of hepatitis B reactivation significant? Pediatr Infect Dis J, 2021, 40(1):11-15.
[12] Ge Z, Ma J, Qiao B, et al. Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality. Medicine (Baltimore). 2020,99(32): e21454.
[13] Wang W, Li X, Xu J. Magnesium isoglycyrrhizinate attenuates D-galactosamine/lipopolysaccharides induced acute liver injury of rat via regulation of the p38-MAPK and NF-κB signaling pathways. Immunopharmacol Immunotoxicol, 2018, 40(3):262-267.
[14] Banga J, Nizami S, Slim J, et al. Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population. Medicine, 2020, 99(11):e19140.
[15] Li C, Liang J, Xiang H, et al. Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C. Medicine, 2020, 99(48):e23384.
[16] Ye H, Teng J, Lin Z, et al. Analysis of HBsAg mutations in the 25 years after the implementation of the hepatitis B vaccination plan in China. Virus genes, 2020, 56(5):546-556.
[17] 黄风雷, 张国梁, 李永生. 中西医结合治疗对乙型肝炎肝硬化失代偿期患者外周血Th/Treg平衡及淋巴细胞的影响研究. 世界中医药, 2019, 14(6):1450-1454,e1460.
[18] Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology (Oxford), 2019, 58(6):1075-1085.
[19] Comarmond C, Lorin V, Marques C,et al. TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses. J Hepatol,2019, 71(5):908-919.
[20] Boni C, Janssen H, Rossi M, et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology, 2019, 157(1):227-241.

标准免疫抑制疗法联合异甘草酸镁治疗自身免疫性肝炎患者外周血B细胞和调节性B细胞变化^*

Peripheral blood regulatory B cell subset changes in patients with autoimmune hepatitis undergoing magnesium isoglycyrrhizinate and standard immunosuppressive therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.
[2]	宋涛, 徐敏, 党子龙, 孙珺珺. 恩替卡韦联合α-干扰素治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 785-788.
[3]	高丽娟, 李永库, 董新颖, 杨艺宁, 冷雪君. 艾米替诺福韦治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 789-792.
[4]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[5]	曹汴川, 刘梅, 丁苹, 汤玲毓, 郭明贤, 周仙, 袁天茹, 严一凯, 黄富礼, 黄永茂. 格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 801-804.
[6]	王卓雅, 吴洋鹏, 黄益桃. 还原型谷胱甘肽联合护肝清脂片治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 823-826.
[7]	阎道博, 朱海超, 闪海霞. 瞬时弹性成像联合APRI诊断自身免疫性肝炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 831-834.
[8]	杨开宁, 王梦梦, 王占坤, 陈秀秀, 肖剑, 王永丽. 注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 839-842.
[9]	王新月, 周莉, 董金玲, 陈煜. 双重血浆分子吸附系统治疗肝衰竭患者应用甲磺酸萘莫司他与肝素抗凝有效性与安全性比较研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 843-846.
[10]	姜亚超, 尹力, 颜状. “改良三明治夹心法”行ESVD术治疗肝硬化并发食管胃静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 863-866.
[11]	刘公攀, 陈涛, 丁志刚, 任明, 郭兴军, 邵存华, 卢建树. CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 879-882.
[12]	于双杰, 李元元, 毕京峰, 福军亮, 宓余强. ICIs联合TKIs治疗HBV相关肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 891-894.
[13]	刘思宏, 谢琉嘉, 周志明, 许亚春. CEUS联合MRI增强扫描早期评价射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 895-898.
[14]	青秀, 周沙, 刘斌. HIFU消融联合化疗治疗中晚期肝母细胞瘤小儿5年随访研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 911-914.
[15]	刘明, 王金婷, 杨士彦, 杨位轩, 万元春. ESPBD与EST治疗肝硬化合并胆总管结石患者疗效比较^*[J]. 实用肝脏病杂志, 2023, 26(6): 915-918.